AN2 Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ANTX$4.33+8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows used in operating activities | ||
| Net loss | $(43,799) | $(47,834) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,558 | 6,180 |
| Non-cash operating lease expense | — | 53 |
| Net accretion of discount on investments | (2,712) | (1,549) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (8) | (405) |
| Accounts payable | (965) | 2,660 |
| Accrued compensation | (1,908) | 28 |
| Accrued liabilities | (1,760) | 3,727 |
| Operating lease liabilities | — | (53) |
| Other current liabilities | 610 | 973 |
| Net cash used in operating activities | (43,984) | (36,220) |
| Cash flows from investing activities | ||
| Purchases of investments | (22,371) | (112,348) |
| Maturities of investments | 83,840 | 68,650 |
| Net cash provided by (used in) investing activities | 61,469 | (43,698) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from the Underwritten Offering, net of commissions and offering expenses | — | 65,800 |
| Proceeds from issuance of common stock from the "at-the-market" offering, net of commissions and offering expenses | — | 19,050 |
| Proceeds from issuance of common stock under the ESPP | 147 | 366 |
| Proceeds from exercise of stock options | 225 | 99 |
| Net cash provided by financing activities | 372 | 85,315 |
| Net increase in cash and cash equivalents | 17,857 | 5,397 |
| Cash and cash equivalents at the beginning of the period | 15,647 | 27,219 |
| Cash and cash equivalents at the end of the period | $33,504 | $32,616 |
| Supplemental disclosure of noncash financing items | ||
| Deferred offering costs included in accounts payable and accrued liabilities | $— | $321 |
AN2 Therapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.